PMID- 25441686
OWN - NLM
STAT- MEDLINE
DCOM- 20150129
LR  - 20141202
IS  - 2210-7762 (Print)
VI  - 207
IP  - 7-8
DP  - 2014 Jul-Aug
TI  - Population-based characterization of the genetic landscape of chronic lymphocytic 
      leukemia patients referred for cytogenetic testing in British Columbia, Canada: 
      the role of provincial laboratory standardization.
PG  - 316-25
LID - S2210-7762(14)00173-2 [pii]
LID - 10.1016/j.cancergen.2014.08.006 [doi]
AB  - Detection of recurrent chromosome abnormalities by fluorescence in situ 
      hybridization (FISH) is an essential component of care in chronic lymphocytic 
      leukemia (CLL) patients. In the province of British Columbia (BC), Canada, 
      population 4.6 million, CLL patients receive uniform evaluation and therapy with 
      FISH testing performed in three jurisdictions. The aims of this study were to (i) 
      validate CLL-FISH testing among the BC cytogenetic laboratories to ensure 
      standardization of results and (ii) characterize population-level CLL-FISH 
      abnormalities by pooling provincial data. From 2004 to 2011, 585 consecutive 
      patients underwent pretreatment CLL-FISH testing at laboratory A (50.1%), 
      laboratory B (32.3%), or laboratory C (17.6%). For validation purposes, 26 
      CLL-FISH abnormalities were tested by each laboratory's protocol, with 91% result 
      concordance. Discordant results involved percent abnormalities at or near cutoff 
      values; therefore, a 10% universal cutoff was established when pooling results. 
      Applying the universal cutoff to the provincial cohort, CLL-FISH abnormalities 
      were detected in 74.9%: 54.9% 13q-, 18.8% +12, 8.5% 11q-, and 7.7% 17p-. In this 
      large population-based cohort of patients referred for CLL-FISH testing, 
      frequencies of abnormalities detected by FISH analysis were highly consistent 
      with those reported in single-institution and clinical trial populations. 
      Provinces or districts that work together to care for CLL patients can 
      effectively pool data with appropriate laboratory validation to ensure 
      standardization of results.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Gerrie, Alina S
AU  - Gerrie AS
AD  - Leukemia/BMT Program of BC, Vancouver General Hospital and British Columbia 
      Cancer Agency, University of British Columbia, Vancouver, Canada.
FAU - Huang, Steven J T
AU  - Huang SJ
AD  - Leukemia/BMT Program of BC, Vancouver General Hospital and British Columbia 
      Cancer Agency, University of British Columbia, Vancouver, Canada; Pathology and 
      Laboratory Medicine, Vancouver General Hospital, University of British Columbia, 
      Vancouver, Canada.
FAU - Bruyere, Helene
AU  - Bruyere H
AD  - Pathology and Laboratory Medicine, Vancouver General Hospital, University of 
      British Columbia, Vancouver, Canada.
FAU - Dalal, Chinmay
AU  - Dalal C
AD  - Leukemia/BMT Program of BC, Vancouver General Hospital and British Columbia 
      Cancer Agency, University of British Columbia, Vancouver, Canada.
FAU - Hrynchak, Monica
AU  - Hrynchak M
AD  - Cytogenetics Laboratory, Royal Columbian Hospital, New Westminster, Canada.
FAU - Karsan, Aly
AU  - Karsan A
AD  - Cancer Genetics Laboratory, Pathology and Laboratory Medicine, British Columbia 
      Cancer Agency, University of British Columbia, Vancouver, Canada.
FAU - Ramadan, Khaled M
AU  - Ramadan KM
AD  - Division of Hematology, St. Paul's Hospital, University of British Columbia, 
      Vancouver, Canada.
FAU - Smith, Adam C
AU  - Smith AC
AD  - Cancer Genetics Laboratory, Pathology and Laboratory Medicine, British Columbia 
      Cancer Agency, University of British Columbia, Vancouver, Canada; Instituto de 
      Pesquisa Pele Pequeno Principe, Curitiba, Brazil.
FAU - Tyson, Christine
AU  - Tyson C
AD  - Cytogenetics Laboratory, Royal Columbian Hospital, New Westminster, Canada.
FAU - Toze, Cynthia L
AU  - Toze CL
AD  - Leukemia/BMT Program of BC, Vancouver General Hospital and British Columbia 
      Cancer Agency, University of British Columbia, Vancouver, Canada.
FAU - Gillan, Tanya L
AU  - Gillan TL
AD  - Pathology and Laboratory Medicine, Vancouver General Hospital, University of 
      British Columbia, Vancouver, Canada. Electronic address: Tanya.Gillan@vch.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140829
PL  - United States
TA  - Cancer Genet
JT  - Cancer genetics
JID - 101539150
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - British Columbia/epidemiology
MH  - *Chromosome Aberrations
MH  - Chromosome Disorders/diagnosis/epidemiology/*genetics
MH  - Chromosomes, Human/*genetics
MH  - Cohort Studies
MH  - Cytogenetic Analysis/*standards
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*standards
MH  - Laboratories, Hospital/*standards
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/epidemiology/*genetics
MH  - Male
MH  - Middle Aged
MH  - Prognosis
OTO - NOTNLM
OT  - Chronic lymphocytic leukemia
OT  - cytogenetic
OT  - fluorescence in situ hybridization
OT  - population-based
OT  - validation
EDAT- 2014/12/03 06:00
MHDA- 2015/01/30 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/02/15 00:00 [received]
PHST- 2014/08/14 00:00 [revised]
PHST- 2014/08/21 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/01/30 06:00 [medline]
AID - S2210-7762(14)00173-2 [pii]
AID - 10.1016/j.cancergen.2014.08.006 [doi]
PST - ppublish
SO  - Cancer Genet. 2014 Jul-Aug;207(7-8):316-25. doi: 10.1016/j.cancergen.2014.08.006. 
      Epub 2014 Aug 29.